skip to main content
Show Results with:

Results 1 - 10 of 16  for Everything in this catalogue

results 1 2 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Material Type:
Article
Add to My workspace

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Sikic, Branimir I.; Lakhani, Nehal; Patnaik, Amita

Journal of clinical oncology. Volume 37:Issue 12 (2019, April); pp 946-953 -- American Society of Clinical Oncology

Check library holdings

2
Material Type:
Article
Add to My workspace

Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

Cox, Donna S. et al.

The journal of clinical pharmacology. Volume 53:Number 9 (2013, September); pp 946-954 -- Published by John Wiley & Sons Inc on behalf of the American College of Clinical Pharmacology

Online access

3
Material Type:
Article
Add to My workspace

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Gadgeel, Shirish M. et al.

Lung cancer. Volume 125: (2018, November); pp 273-281 -- Elsevier Science Pub. Co

Online access

4
Material Type:
Article
Add to My workspace

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

Tolcher, Anthony et al.

The oncologist. Volume 23:Number 6 (2018, June); pp 658-e72 -- AlphaMed Press

Online access

5
Material Type:
Article
Add to My workspace

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Gubens, Matthew A. et al.

Lung cancer. Volume 130: (2019, April); pp 59-66 -- Elsevier Science Pub. Co

Online access

6
Material Type:
Article
Add to My workspace

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Gadgeel, Shirish M. et al.

Lung cancer. Volume 125 (2018); pp 273-281 -- Elsevier Science Pub. Co

Online access

7
Material Type:
Article
Add to My workspace

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation

Stroh, Mark et al.

The journal of clinical pharmacology. Volume 54:Number 11 (2014, November); pp 1256-1262 -- Published by John Wiley & Sons Inc on behalf of the American College of Clinical Pharmacology

Online access

8
Material Type:
Article
Add to My workspace

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

Tolcher, Anthony et al.

The oncologist. Volume 23:Issue 6 (2018); pp 658-e72 -- AlphaMed Press

Online access

9
Material Type:
Article
Add to My workspace

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Leighl, Natasha B et al.

The lancet. Respiratory medicine. Volume 7:Issue 4 (2019); pp 347-357 -- Elsevier

Online access

10
Material Type:
Article
Add to My workspace

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Leighl, Natasha B et al.

The lancet. Respiratory medicine. Volume 7:Issue 4 (2019); pp 347-357 -- Elsevier

Online access

Results 1 - 10 of 16  for Everything in this catalogue

results 1 2 next page

Refine Search Results

Refine my results

Access Options 

  1. Online: Reading Room only  (13)
  2. Purchase a copy  (6)
  3. Refine further open sub menu

Creation date 

From To

Additional Features 

  1. Abstract  (11)
  2. No Abstract  (5)
  3. Refine further open sub menu

Searching Remote Databases, Please Wait